For patients undergoing heart valve surgery who also have coronary artery disease, a more precise approach to determining which blocked arteries need bypass surgery appears to lead to better outcomes. A large, randomized clinical trial conducted in China has found that guiding bypass decisions with angiography-derived fractional flow reserve (FFR) – a measure of blood flow through an artery – reduces the risk of complications compared to relying solely on traditional angiography, which provides a visual assessment of blockages. This research, published recently, offers compelling evidence for a shift towards physiologically guided coronary artery bypass grafting (CABG) in a complex patient population.
The study, dubbed FAVOR IV-QVAS (Fractional flow reserve-guided versus angiography-guided coronary artery bypass grafting in patients undergoing surgical valve procedures with concomitant coronary artery disease), involved over 600 patients at multiple centers across China. Participants were all scheduled for valve surgery and had been diagnosed with significant coronary artery disease. Traditionally, surgeons have used coronary angiography – essentially an X-ray of the arteries – to identify blockages and decide which vessels to bypass. However, angiography can sometimes overestimate the severity of a blockage, leading to unnecessary bypasses. The FAVOR IV-QVAS trial investigated whether adding FFR assessment, which directly measures how a blockage impacts blood flow, could improve outcomes. The primary outcome measured was a composite of perioperative events, including death, stroke, myocardial infarction, and repeat revascularization.
Researchers randomly assigned patients to either an FFR-guided CABG strategy or an angiography-guided strategy. In the FFR group, doctors used the technology to assess the functional significance of any blockages seen on angiography. If an FFR reading indicated a blockage was significantly restricting blood flow, a bypass was performed. If the FFR was normal, the blockage was left untreated. The angiography group received bypasses based solely on the visual assessment of blockages from the angiogram. The results showed a statistically significant reduction in the primary outcome in the FFR-guided group. Specifically, 14.1% of patients in the FFR group experienced the composite outcome compared to 21.8% in the angiography group, representing a 35% relative risk reduction. The New England Journal of Medicine published the full findings on November 26, 2023.
Understanding Fractional Flow Reserve
FFR is a diagnostic tool used during coronary angiography. It involves temporarily increasing blood flow to the heart and then measuring the pressure difference across a suspected blockage. This pressure difference indicates how much the blockage is restricting blood flow. A reading of 0.80 or higher generally suggests the blockage is not significantly impacting blood flow and doesn’t necessarily require intervention. The American College of Cardiology provides detailed information about FFR and its clinical applications. The technology isn’t new, but its application in guiding CABG decisions during valve surgery is a relatively recent area of investigation.
Why This Matters for Valve Surgery Patients
Patients undergoing valve surgery often have underlying coronary artery disease due to shared risk factors like age, high blood pressure, and diabetes. Deciding whether to perform CABG at the same time as valve surgery is a complex decision. Adding CABG increases the risk of complications, but leaving significant blockages untreated can lead to future heart attacks or angina. The FAVOR IV-QVAS trial suggests that FFR can help doctors make more informed decisions, avoiding unnecessary bypasses and potentially improving overall outcomes. This represents particularly important because the benefits of adding CABG to valve surgery are often debated, and the optimal strategy remains a subject of ongoing research.
The Study Design: A Triple-Blind Approach
The rigor of the FAVOR IV-QVAS trial is noteworthy. It was a triple-blind study, meaning that the patients, the surgeons, and the data analysts were all unaware of which patients were assigned to which group. This minimized the potential for bias in the results. The trial also included a large sample size, increasing the statistical power of the findings. The study’s multicenter design, encompassing multiple hospitals in China, enhances the generalizability of the results to a broader population. The researchers carefully monitored patients for a range of outcomes, providing a comprehensive assessment of the impact of FFR-guided CABG.
Implications and Future Directions
The findings from FAVOR IV-QVAS support a more selective approach to coronary revascularization in patients undergoing valve procedures. Rather than automatically bypassing all visible blockages, doctors can use FFR to identify those that are truly causing significant problems. This could lead to fewer unnecessary surgeries, reduced complications, and improved long-term outcomes. However, it’s important to note that the study was conducted in China, and further research is needed to confirm these findings in other populations. The cost and availability of FFR technology may also be a barrier to widespread adoption in some healthcare systems. The study also did not address the optimal timing of CABG – whether it should be performed at the same time as valve surgery or at a later date.
The researchers are continuing to follow the patients in the FAVOR IV-QVAS trial to assess long-term outcomes, including survival rates and the incidence of future cardiovascular events. These longer-term data will provide further insights into the benefits and risks of FFR-guided CABG. Ongoing research is also exploring the use of other physiological assessment tools, such as instantaneous wave-free ratio (iFR), to guide coronary revascularization decisions. The goal is to personalize treatment strategies and provide the best possible care for each patient. The next major update from the FAVOR IV-QVAS team is expected in late 2024, when the five-year follow-up data will be available.
This research represents a significant step forward in optimizing the care of patients undergoing valve surgery with concomitant coronary artery disease. By incorporating physiological assessment into the decision-making process, doctors can move beyond simply looking at blockages and focus on treating those that are truly impacting blood flow and threatening heart health.
Disclaimer: This article is for informational purposes only and should not be considered medical advice. Please consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
Have you or a loved one faced decisions about coronary artery bypass grafting? Share your experiences and thoughts in the comments below. Please also share this article with anyone who might find this information helpful.
